Summary

The Global Tissue Diagnostics Market is valued at approximately USD 6.11 billion in 2024 and is expected to register a promising CAGR of 8.40% over the forecast period of 2025-2035. Tissue diagnostics—considered a cornerstone in modern pathology—plays a critical role in cancer diagnostics and prognostics, enabling the precise identification of cellular anomalies through tissue samples. At the heart of this transformation lies the increasing demand for personalized medicine, rising cancer prevalence, and growing reliance on immunohistochemistry (IHC) and in-situ hybridization (ISH) techniques to guide therapeutic decisions. This mounting reliance on early, reliable, and tissue-based diagnostics, particularly across oncology, is catalyzing industry expansion, as hospitals and diagnostic labs endeavor to improve accuracy and turnaround times. The steady introduction of technologically advanced instruments, alongside a spike in consumable demand, continues to reinforce the market’s upward trajectory.
Simultaneously, the uptick in global cancer cases, especially breast, prostate, and hematological malignancies such as lymphoma, is intensifying the need for tissue diagnostics across the care continuum. According to WHO statistics, cancer is projected to account for nearly 29 million cases globally by 2040, which is significantly influencing diagnostics pipelines. Furthermore, advancements in slide staining automation, digital scanning systems, and next-generation tissue processing platforms are setting new standards in laboratory efficiency. Increased emphasis on biomarker discovery and companion diagnostics is also propelling investments in consumables like antibodies and probes, underscoring their role in treatment path selection. However, the high cost of these advanced diagnostic solutions and infrastructure limitations in underdeveloped economies remain barriers that stakeholders must work around.
From a regional perspective, North America currently dominates the global tissue diagnostics landscape, owing to its robust healthcare infrastructure, established regulatory frameworks, high penetration of advanced diagnostic modalities, and the presence of leading industry players. The United States, in particular, exhibits a strong focus on precision medicine, with rising R&D investments in oncology diagnostics. Meanwhile, Asia Pacific is forecasted to be the fastest-growing region over the next decade. Rapidly expanding healthcare systems, coupled with increasing cancer burden in populous nations such as China and India, are prompting higher diagnostic awareness and screening initiatives. Supportive policy frameworks, healthcare digitalization, and the proliferation of diagnostic laboratories are further driving demand. Europe also holds a substantial market share, supported by government-funded cancer screening programs and growing adoption of molecular diagnostic platforms.
Major market player included in this report are:
• Roche Diagnostics
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Agilent Technologies Inc.
• Danaher Corporation
• Siemens Healthineers AG
• BioGenex Laboratories
• Sakura Finetek USA, Inc.
• Merck KGaA
• Becton, Dickinson and Company
• Bio-Techne Corporation
• Abcam plc
• Biocare Medical, LLC
• QIAGEN N.V.
• Enzo Life Sciences, Inc.
Global Tissue Diagnostics Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period – 2025-2035
• Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope – Free report customization (equivalent up to 8 analysts’ working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:
By Product:
• Consumables
o Antibodies
o Reagents
o Tissue
o Probes
• Instruments
o Processing System
o Scanner
By Technology:
• ISH (In-Situ Hybridization)
• IHC (Immunohistochemistry)
• Slide Staining
By Disease Type:
• Breast Cancer
• Lymphoma
• Prostate Cancer
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1. Global Tissue Diagnostics Market Report Scope & Methodology
1.1. Research Objective
1.2. Research Methodology
1.2.1. Forecast Model
1.2.2. Desk Research
1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
1.4.1. Market Definition
1.4.2. Market Segmentation
1.5. Research Assumption
1.5.1. Inclusion & Exclusion
1.5.2. Limitations
1.5.3. Years Considered for the Study
Chapter 2. Executive Summary
2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. Key Findings
Chapter 3. Global Tissue Diagnostics Market Forces Analysis (2024-2035)
3.1. Market Forces Shaping the Global Tissue Diagnostics Market
3.2. Drivers
3.2.1. Rising Cancer Prevalence and Demand for Early Diagnosis
3.2.2. Advancements in Diagnostic Technologies (e.g., IHC, ISH)
3.2.3. Growth in Personalized Medicine and Biomarker-Based Testing
3.3. Restraints
3.3.1. High Cost of Advanced Diagnostic Tools and Infrastructure
3.3.2. Limited Access in Developing Regions
3.4. Opportunities
3.4.1. Expansion of Molecular Diagnostic Applications in Oncology
3.4.2. Increasing Investments in Healthcare Infrastructure in Emerging Markets
Chapter 4. Global Tissue Diagnostics Industry Analysis
4.1. Porter’s 5 Forces Model
4.1.1. Bargaining Power of Buyer
4.1.2. Bargaining Power of Supplier
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Porter’s 5 Force Forecast Model (2024–2035)
4.3. PESTEL Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.3.5. Environmental
4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2024–2025)
4.7. Global Pricing Analysis and Trends 2025
4.8. Analyst Recommendation & Conclusion
Chapter 5. Global Tissue Diagnostics Market Size & Forecasts by Product (2025–2035)
5.1. Market Overview
5.2. Consumables
5.2.1. Antibodies
5.2.2. Reagents
5.2.3. Tissue
5.2.4. Probes
5.3. Instruments
5.3.1. Processing System
5.3.2. Scanner
Chapter 6. Global Tissue Diagnostics Market Size & Forecasts by Technology (2025–2035)
6.1. Market Overview
6.2. ISH (In-Situ Hybridization)
6.3. IHC (Immunohistochemistry)
6.4. Slide Staining
Chapter 7. Global Tissue Diagnostics Market Size & Forecasts by Disease Type (2025–2035)
7.1. Market Overview
7.2. Breast Cancer
7.3. Lymphoma
7.4. Prostate Cancer
Chapter 8. Global Tissue Diagnostics Market Size & Forecasts by Region (2025–2035)
8.1. Global Tissue Diagnostics Market, Regional Market Snapshot
8.2. Top Leading & Emerging Countries
8.3. North America Tissue Diagnostics Market
8.3.1. U.S.
8.3.1.1. Product breakdown size & forecasts (2025–2035)
8.3.1.2. Technology breakdown size & forecasts (2025–2035)
8.3.1.3. Disease Type breakdown size & forecasts (2025–2035)
8.3.2. Canada
8.3.2.1. Product breakdown size & forecasts (2025–2035)
8.3.2.2. Technology breakdown size & forecasts (2025–2035)
8.3.2.3. Disease Type breakdown size & forecasts (2025–2035)
8.4. Europe Tissue Diagnostics Market
8.4.1. UK
8.4.2. Germany
8.4.3. France
8.4.4. Spain
8.4.5. Italy
8.4.6. Rest of Europe
8.5. Asia Pacific Tissue Diagnostics Market
8.5.1. China
8.5.2. India
8.5.3. Japan
8.5.4. Australia
8.5.5. South Korea
8.5.6. Rest of Asia Pacific
8.6. Latin America Tissue Diagnostics Market
8.6.1. Brazil
8.6.2. Mexico
8.7. Middle East and Africa Tissue Diagnostics Market
8.7.1. UAE
8.7.2. Saudi Arabia
8.7.3. South Africa
8.7.4. Rest of Middle East & Africa
Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Roche Diagnostics
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Financial Performance (Subject to Data Availability)
9.2.5. Product/Services Port
9.2.6. Recent Development
9.2.7. Market Strategies
9.2.8. SWOT Analysis
9.3. Abbott Laboratories
9.4. Thermo Fisher Scientific Inc.
9.5. Agilent Technologies Inc.
9.6. Danaher Corporation
9.7. Siemens Healthineers AG
9.8. BioGenex Laboratories
9.9. Sakura Finetek USA, Inc.
9.10. Merck KGaA
9.11. Becton, Dickinson and Company
9.12. Bio-Techne Corporation
9.13. Abcam plc
9.14. Biocare Medical, LLC
9.15. QIAGEN N.V.
9.16. Enzo Life Sciences, Inc.